Slowing the Progression of Smoldering Myeloma
Dexamethasone is often referred to as “dex” for short. Some brand names for dexamethasone are Decadron, Dexasone, Diodex, Hexadrol, Maxidex.
This article reports preliminary results from an NCI‑supported phase 2 and phase 3 clinical trial evaluating lenalidomide as a single agent in patients with smoldering myeloma classified as high‑risk. In the phase 3 study, 182 patients were randomized to lenalidomide or observation. After 3 years, 91 % of patients receiving lenalidomide remained progression‑free compared with 66 % in the observation arm, suggesting a significant reduction in the risk of developing symptomatic multiple myeloma. Side‑effects such as fatigue and neutropenia led to dose interruptions or discontinuation in a substantial proportion of participants, indicating that therapeutic monitoring and dose adjustment may be necessary.
This statement identifies the common abbreviation (“dex”) and lists several brand names for dexamethasone, which is useful for both clinicians and patients when interpreting prescribing information and medication lists.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Multiple Myeloma Clinical Trials & Emerging Therapies
- A single‑cell atlas of multiple myeloma defines malignant archetypes and proliferative states
- S2209: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM)
- Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study
- Nanomedicine-Empowered CAR‑T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy